1. Introduction {#sec1-antibiotics-09-00265}
===============

Activity in general practice has increased significantly over the past five years, with the average person visiting their general practice around six times a year \[[@B1-antibiotics-09-00265]\]. Most primary care consultations (52%) are conducted by a general practitioner (GP) and 82% of all appointments are face to face \[[@B2-antibiotics-09-00265]\]. However, overall patient satisfaction with general practice has declined \[[@B1-antibiotics-09-00265]\]. Initiatives to improve patient care mean that multiple actions are needed for each patient, e.g., screening, monitoring and other disease management tasks, which presents a challenge to GPs working to a 10-min consultations model.

Antimicrobial resistance (AMR) is perhaps the biggest threat to modern medicine and it will still be even after the COVID-19 pandemic. The majority of antibiotics in England, 81%, are prescribed in primary care \[[@B3-antibiotics-09-00265]\] and is likely to increase during the COVID-19 pandemic due to remotely prescribed and broad-spectrum antibiotics. Across the UK, general practice is the first port of call for many people presenting with an infectious disease \[[@B3-antibiotics-09-00265],[@B4-antibiotics-09-00265],[@B5-antibiotics-09-00265]\]; penicillins are the most commonly prescribed antibiotic group in this setting (46.5%) by items prescribed per 1000 inhabitants per day, followed by tetracyclines (13%), then macrolides (11.7%) \[[@B3-antibiotics-09-00265]\]. Similar trends have been observed in other UK nations \[[@B4-antibiotics-09-00265],[@B5-antibiotics-09-00265]\].

The overprescribing of antibiotics is a major driver for antibiotic resistance. In 2018, research estimated that at least 20% of antibiotics are prescribed inappropriately in England, many of these for respiratory tract infections (RTIs) \[[@B6-antibiotics-09-00265]\]. It was found that 41% of acute cough consultations were prescribed antibiotics when only 10% were deemed appropriate \[[@B7-antibiotics-09-00265]\]. A recent systematic review highlighted diagnostic uncertainty as a contributing factor for overprescribing for acute RTIs \[[@B8-antibiotics-09-00265]\]. Researchers also found that consistently available national guidelines on antibiotic prescribing, were regarded as important by clinicians for their prescribing decision making. As such, this study aims to identify current gaps in knowledge, skills, guidance and research from the GP's point of view as \[[@B1-antibiotics-09-00265],[@B2-antibiotics-09-00265],[@B6-antibiotics-09-00265],[@B7-antibiotics-09-00265]\] this will facilitate improved antimicrobial stewardship.

In a 1999 survey of GPs, we found that genital chlamydia infection, antibiotic resistance surveillance, vaginal discharge, leg ulcers, sinusitis, otitis media/externa, dyspepsia/Helicobacter pylori, Creutzfeldt--Jakob disease (CJD) and tonsillitis were the top 10 priorities for improvements to diagnostic tests, and stronger evidence on which to base treatment decisions \[[@B9-antibiotics-09-00265],[@B10-antibiotics-09-00265]\]. The present study will also compare findings from the 1999 study.

2. Results {#sec2-antibiotics-09-00265}
==========

2.1. Response Rate {#sec2dot1-antibiotics-09-00265}
------------------

Of those who opened the online survey, 12% (428/3526) completed all questions, not all participants completed all questions.

For those who completed the demographic data section of the survey, 97% (349/361) of respondents were from England, with 1% from each of the other devolved administrations (Scotland 5/361; Wales 4/361; Northern Ireland 3/361). The response rate by region of England is shown in [Figure 1](#antibiotics-09-00265-f001){ref-type="fig"}. 15% (54/360) of respondents self-identified as being from rural practices.

In total, 48% (174/361) of respondents stated that they were from a research practice. A total of 32% (118/370) reported receiving the survey from the Royal College of General Practitioners (RCGP), 22% (80/370) from the CRN, 31% (115/370) from their local CCG, 7% (25/370) from a colleague, 3% from RCGP First 5 group (10/370) and 6% (22/370) from another source. Gender, age and years in practice data can be found in [Table 1](#antibiotics-09-00265-t001){ref-type="table"}.

2.2. Representativeness of the Data {#sec2dot2-antibiotics-09-00265}
-----------------------------------

[Table 1](#antibiotics-09-00265-t001){ref-type="table"} demonstrates that there were no differences in the characteristics of GPs in the final sample of survey respondents and those of all GPs in the sample frame, in terms of age and sex. There was a slight over-representation of GPs stating they were from a research practice compared with GPs in the sample frame and respondents were overrepresented from the South West and underrepresented from the East of England; Yorkshire and Humber; and London.

2.3. Condition Ranking {#sec2dot3-antibiotics-09-00265}
----------------------

Of the 27 named conditions/illnesses, suspected infection in the elderly (82.2%), recurrent urinary tract infection (UTI) (81.2%), surveillance of antibiotic resistance in the community (81.0%), leg ulcers (75.4%), and persistent cough (75.2%) were the five most highly rated illness/conditions where respondents felt they required more evidence to support their daily practice. Weighted scores for all 27 named conditions are shown in [Figure 2](#antibiotics-09-00265-f002){ref-type="fig"}. Ranking did not differ between research and non-research practices ([Table A1](#antibiotics-09-00265-t0A1){ref-type="table"}). Condition ranking compared to the 1999 study can be seen in [Table 2](#antibiotics-09-00265-t002){ref-type="table"}.

2.4. Top Three Illnesses/Conditions That Require Further Research, Evidence and Guidance {#sec2dot4-antibiotics-09-00265}
----------------------------------------------------------------------------------------

From the list of 21 named conditions, respondents were asked to identify the top three illnesses/conditions they felt required further research, evidence and guidance. [Table 2](#antibiotics-09-00265-t002){ref-type="table"} illustrates that the five most frequently named illnesses/conditions by GPs that require further research, evidence and guidance, were similar to the top five ranked illnesses/conditions. A total of 115 respondents added both suspected infection in the elderly and surveillance of antibiotic resistance in the community in their top three conditions, resulting in these conditions being ranked joint first place, followed by recurrent UTI, persistent cough, cellulitis and leg ulcers, in that order. Ranking did not differ between research and non-research practices ([Table A1](#antibiotics-09-00265-t0A1){ref-type="table"}).

### Other Conditions

Participants (55%; 239/234) identified over 170 'other' areas that required further research. The most frequently identified areas were mental health (13.07%; 63 mentions), pain management (6.93%; 35 mentions), skin conditions (5.88%; 30 mentions) and chronic fatigue or fibromyalgia (5.54%; 28 mentions).

2.5. Type of Evidence, Research and Guidance Needed {#sec2dot5-antibiotics-09-00265}
---------------------------------------------------

[Table 3](#antibiotics-09-00265-t003){ref-type="table"} shows rankings for which areas of research (near patient antibiotic resistance test; clinical scores to help inform management; or point of care prognostic tests), evidence (evidence base for antibiotic treatment; evidence base for self-care and non-antibiotic treatment) or guidance (improved treatment guidelines) respondents felt were required for each condition/illness. The top three priorities across all 27 named conditions were the 'need for better evidence base for antibiotic treatment' (exceptions: viral hepatitis and HIV/AIDS); the 'need for improved treatment guidelines for primary care staff' (exceptions: acute cough and surveillance of AMR in the community); and the 'need for better evidence base for self-care and non-antibiotic treatment in primary care' (exceptions: genital chlamydia, Lyme disease and suspected infection in the elderly and tuberculosis (TB)). There was little variation between the ranking of the 'need for better clinical scores to help inform management in primary care' (exceptions: viral hepatitis, otitis externa, prostatitis, tonsillitis and TB) and the 'need for better point of care prognostic tests in primary care' (exception: genital chlamydia), with both being ranked in either the 4th or 5th position. The need for better near patient antibiotic resistance test in primary care was the lowest ranked respondent priority across all conditions/illnesses (exceptions: AMR in returning travelers and genital chlamydia).

3. Discussion {#sec3-antibiotics-09-00265}
=============

The conditions for which a GP said they wanted more evidence to support their daily practice and require further research, evidence and guidance were: suspected infection in the elderly; recurrent UTI; surveillance of antimicrobial resistance in the community; leg ulcers; persistent cough; and cellulitis. The need for a better evidence base for antibiotic treatment in primary care; the need for improved treatment guidelines for primary care staff; and the need for better evidence base for self-care and non-antibiotic treatment in primary care were considered the most important service developments. The need for better point-of-care prognostic test, clinical scores to inform management, and near patient antibiotic susceptibility tests were considered less important.

3.1. Strengths and Limitations {#sec3dot1-antibiotics-09-00265}
------------------------------

To improve response rates, the survey was disseminated via relevant GP channels in England but we have no information as to how many GPs actually received the invitation to participate in the survey. Survey site data suggest that internal surveys generally receive a 30--40% response rate compared with 10--15% for external surveys \[[@B12-antibiotics-09-00265],[@B13-antibiotics-09-00265]\], which is in line with our findings regarding how many people opened the survey vs. how many people actually completed it.

Demographic data indicates that respondents were generally representative of GPs in England by age, gender and years in practice distribution. Percentage response rates for age and gender were similar to national data \[[@B11-antibiotics-09-00265],[@B14-antibiotics-09-00265]\], and our findings show no differences between GP practice research status and rating of importance of more evidence.

We did not collect data on respondent workplace and have assumed independence in all analysis which may be considered a limitation.

The provision of a named list of conditions helped reduce seasonal or respondent bias towards specific conditions. The 'other' option allowed respondents to add conditions they felt were important but were not on the main list.

3.2. Comparison with Existing Literature {#sec3dot2-antibiotics-09-00265}
----------------------------------------

The last UK GP survey of this nature was conducted in 1999 and found genital chlamydia infection to be the number one priority for 'improvements to diagnostic tests, evidence on which to base treatment, and guidance' \[[@B9-antibiotics-09-00265],[@B10-antibiotics-09-00265]\]. Interestingly a 40-fold variation in testing rates across GP practices was observed at this time \[[@B15-antibiotics-09-00265]\]. The drop to position 23 for Chlamydia, and the drop from the 4th position to 12th position for vaginal discharge in the latest survey, may be attributed to the introduction of evidence-based national guidelines and standards for UK specialists in genitourinary medicine \[[@B16-antibiotics-09-00265]\] and STIs \[[@B17-antibiotics-09-00265]\] and the establishment of the national chlamydia screening programme (NCSP) in 2002 \[[@B18-antibiotics-09-00265]\]; the latter of which contributed to a reduction in the prevalence and average duration of infections following implementation \[[@B19-antibiotics-09-00265]\].

Other conditions that have dropped out of the top 10 position since the 1999 survey included a range of respiratory tract infections (RTIs), suggesting that GPs feel the evidence base for diagnosis and treatment of these conditions is adequate. Much research has gone into developing evidence-based guidelines for RTIs \[[@B20-antibiotics-09-00265],[@B21-antibiotics-09-00265]\] and clinical prediction tools in recent years for self-limiting RTIs \[[@B22-antibiotics-09-00265],[@B23-antibiotics-09-00265],[@B24-antibiotics-09-00265],[@B25-antibiotics-09-00265],[@B26-antibiotics-09-00265]\]. Health professional training workshops and toolkits \[[@B27-antibiotics-09-00265]\] may also account for the increase in GP confidence to treat these infections. Public education campaigns aimed at reducing patient expectations for antibiotics and focussing on RTIs have resulted in a decrease in the expectation of antibiotics for these conditions and for consultations with a cough or cold \[[@B28-antibiotics-09-00265]\].

Venous leg ulcers and persistent sinusitis have remained in the top 10 with the need for improved treatment guidelines a named priority area. A recent systematic review \[[@B29-antibiotics-09-00265]\] found only four clinical practice guidelines worldwide (none in England) on venous leg ulcers, between 1999 and 2016, considered to be of adequate quality for clinical use. There have been few clinical trials on the antibiotic treatment of leg ulcers; more research has gone into non-antibiotic treatment and the chronic relapsing nature of the condition, highlighting the complexity of treatments for GP staff to follow \[[@B30-antibiotics-09-00265]\]. In February 2020, the UK National Institute for Health and Care Excellence (NICE) developed antibiotic prescribing guidance for leg ulcer infection \[[@B31-antibiotics-09-00265]\].

For persistent sinusitis, GPs ranked the need for a better evidence base for self-care and non-antibiotic treatment as a priority area. Design variation in studies investigating the effects of antibiotic use for chronic rhinosinusitis make drawing firm conclusions in systematic reviews difficult \[[@B32-antibiotics-09-00265],[@B33-antibiotics-09-00265],[@B34-antibiotics-09-00265]\]. A Cochrane review concluded that there was little evidence that systemic antibiotics are effective in patients with chronic rhinosinusitis and that more research in the field is required \[[@B33-antibiotics-09-00265]\]. NICE published specific Managing Common Infection guidance for acute sinusitis \[[@B35-antibiotics-09-00265]\] of less than four weeks with sudden onset of symptoms, but there is no UK guidance available for persistent sinusitis.

An observed increase in the incidence of blood stream infections associated with urinary tract infections (UTI) and increasing AMR may account for the elevation of recurrent UTI to 2nd place in 2017 from 18th in 1999 \[[@B9-antibiotics-09-00265]\]. During the time of the survey, NHS England implemented a mandate to reduce inappropriate antibiotic prescribing for UTI in primary care \[[@B36-antibiotics-09-00265]\], which may account for the greater interest in the treatment of UTIs, which represent 1--3% of UK primary care consultations. GPs in our survey recorded a 'need for a better evidence base for self-care and non-antibiotic treatment' and 'the need for a better evidence base for antibiotic treatment' as their two priority areas, followed by 'the need for improved treatment guidelines'. Although antibiotic prescribing guidelines have been available for suspected bacterial UTIs in the UK, none focussed on recurrent UTIs. Since this study was conducted, NICE have published antimicrobial prescribing guidance for lower, upper, recurrent and catheter-associated UTI \[[@B37-antibiotics-09-00265]\].

Interestingly, GPs' ranking of Tuberculosis (TB), 19/27 (*n* = 411), remains unchanged, with only eight individuals placing it in their top three most important conditions. This is surprising as, due to its resistance to a wide range of antimicrobials, TB is named in the Department of Health 5-year strategy \[[@B38-antibiotics-09-00265]\] and 20-year vision \[[@B39-antibiotics-09-00265]\] for antimicrobial resistance. The lower priority of TB in this survey may be because TB infections are mostly diagnosed in the London area \[[@B40-antibiotics-09-00265]\], and only 10% of our respondents were from this region.

Suspected infection in the elderly, prostatitis, and diverticulitis were ranked in the top 10 of conditions for which GPs required evidence to support their daily practice; (ranked first, eighth and ninth respectively). These conditions were not given as an option in the 1999 study therefore we cannot compare our findings. For prostatitis and diverticulitis GPs ranked the need for a better evidence base for antibiotic treatment and improved treatment guidelines as priority areas. At the time of the 2017 survey, there was no antibiotic prescribing guidance for these conditions in England; however, NICE have since launched their first antimicrobial prescribing guidance for both acute prostatitis (2018) \[[@B41-antibiotics-09-00265]\] and diverticular disease (2019) \[[@B42-antibiotics-09-00265]\]. There is still a need for a greater evidence base in both these conditions \[[@B41-antibiotics-09-00265],[@B42-antibiotics-09-00265]\].

It is not surprising that suspected infection in the elderly was ranked as the top condition for which GPs required evidence to support their daily practice as this group has higher infectious disease morbidity \[[@B40-antibiotics-09-00265],[@B43-antibiotics-09-00265]\]. The UK population is also getting older; the number of UK residents aged 65 and over has increased by 2.7 million in the past 25 years and is expected to rise by a further 8.6 million in the next 50 years \[[@B44-antibiotics-09-00265]\]. This increase in life expectancy has a knock-on effect on our health services, with antibiotic prescribing rates being the highest in this age group \[[@B45-antibiotics-09-00265]\]. In a recent study, GPs used antibiotic treatment both as a diagnostic aid and in an attempt to avoid hospital admission and felt that, in some cases, restrictions on antibiotic use potentially hampered optimal management of infection in this age group \[[@B46-antibiotics-09-00265]\]. Similar to our findings, authors concluded that research that can fill the gaps in the evidence base is required in order to support GPs with their critical antimicrobial stewardship role in this population.

Over 60% of bacteraemia occurs in over 65 year olds who have a 13-fold higher risk of developing sepsis \[[@B47-antibiotics-09-00265]\]. The need for a better evidence base for antibiotic treatment and improved treatment guidelines were ranked as the top two GP priorities.

4. Materials and Methods {#sec4-antibiotics-09-00265}
========================

An online questionnaire survey, based on a previous survey from 1999 \[[@B9-antibiotics-09-00265]\], was used to collect data from GPs across the UK. For this study researchers chose to focus on 27 common conditions/illnesses based on their clinical expertise. The survey was designed and tested by researchers, GPs and microbiologists at Public Health England (PHE). The survey comprised three sections, with multiple fixed questions and one open question ([Appendix A](#app1-antibiotics-09-00265){ref-type="app"}):Participant rating of 27 named illnesses/conditions based on how much more evidence they perceive is required to support daily practice.Participant selection of the top three illnesses/conditions that they perceive require further research, evidence and guidance, with participant identification of where those improvements are required.Demographic data collection.

The survey was implemented using SelectSurvey (SelectSurvey.NETv4, ClassApps LLC, Kansas City, MO, USA).

4.1. Survey Dissemination {#sec4dot1-antibiotics-09-00265}
-------------------------

A link to the survey and a covering letter were disseminated to GPs between June and November 2017 via the Royal College of General Practitioners newsletter (RCGP) (*n* ≥ 2000 individual members and to 230 practices); the regional Clinical Research Network (CRN) leads (*n* = 15), via email, for distribution to their members; and all Clinical Commissioning Group (CCG) medicine managers (*n* = 161) via e-mail, for distribution to their GPs.

4.2. Data Management {#sec4dot2-antibiotics-09-00265}
--------------------

Data were exported from SelectSurvey to Stata (Stata Statistical Software: Release 13. StataCorp LP, College Station, TX, USA) for analysis. Survey items that asked respondents to rate priorities on a Likert scale were given an overall percentage score, which was calculated by dividing a weighted sum of individual responses (coded as very unimportant = 1, very important = 5) by the theoretical maximum score.

For the top three illness/condition sections of the survey where different respondents may have rated the same illness/condition in either the number 1, 2 or 3 position, the total number of respondents selecting a particular illness/condition were added together to give the final overall ranking.

4.3. Representativeness of the GP Sample {#sec4dot3-antibiotics-09-00265}
----------------------------------------

Statistical comparisons, using the Chi-square test (significant at the 5% level), were made between the survey respondents and all recognised GPs in the sample frame during the study period ([Table 1](#antibiotics-09-00265-t001){ref-type="table"}). The GP characteristics data for the respondents were taken from their survey responses, while the data for all GPs in the sample frame were obtained from NHS Digital \[[@B11-antibiotics-09-00265]\].

4.4. Comparison of Importance of Research between GPs from Research and Non-Research Practices {#sec4dot4-antibiotics-09-00265}
----------------------------------------------------------------------------------------------

Research practices are defined as GP practices that actively take part in research projects. For each condition ordinal logistic regression was used to assess the association between research practice and rating, without adjusting for any other covariate. This association was also assessed after simultaneously adjusting for gender, years, location, rurality and audit, the remaining being omitted due to strong collinearity between them and the other covariates. Where this was not possible, a model was developed by means of a forwards stepwise approach wherein non-significant (at the 5% level), not substantially confounding covariates (a covariate was a substantial confounder if its removal resulted in a greater than 10% change in the odds ratios (ORs) of one or more of the parameters still in the model) were removed, but always retaining research practice. If none of the covariates were found to be significant or confounding, the unadjusted association between research practice and rating is presented. The proportional odds assumption was tested by means of a likelihood ratio test (LRT) and, if significant at the 5% level, a generalised ordered logit model was fitted wherein the proportionality assumption was relaxed for those parameters not meeting the criterion, as detailed in the reference. The likelihood ratio test LRT was used to obtain determine significance, except when the generalised ordered logit model was used, in which case the p-value was obtained from the Wald test. The measure of association for research practice quoted was the odds ratio (OR), together with 95% confidence intervals (CIs).

5. Conclusions {#sec5-antibiotics-09-00265}
==============

This survey has highlighted areas of topic prioritisation for the development of guidance and future research areas. Since the 1999 survey, investment in research, evidence-based treatment guidelines, training, clinical prediction tools and screening programmes for many of the common infections may have led to the decreased prioritisation of acute RTIs by GPs. The focus for research to support diagnostic and management guidance now needs to be on less common and chronic infections. We are encouraged that NICE and PHE have already developed antibiotic prescribing guidance for some of these conditions \[[@B31-antibiotics-09-00265],[@B35-antibiotics-09-00265],[@B37-antibiotics-09-00265],[@B41-antibiotics-09-00265],[@B42-antibiotics-09-00265]\]; however, three of the top 10 conditions where GPs required evidence to support their daily practice future were for chronic or recurring conditions, i.e., chronic sinusitis, chronic cough, recurring UTI, for which there is currently little or no diagnostic, management or treatment guidelines.
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Section 1
=========

1.  On a scale of 1--5, please indicate how much more evidence you would like to see for each of the following conditions to support your daily clinical practice. (Tick one box for each statement. Please note that conditions are in alphabetical order) AMR in returning travellersCellulitisChlamydia GenitalCough AcuteCough PersistentDiverticulitisEpididymitis/OrchitisFungal nail infections in the communityHepatitis ViralHIV/AIDSInfection in Returning TravellersInsect Bites, possible skin infectionsLeg UlcersLyme DiseaseMastitisOtitis ExternaOtitis MediaProstatitisSinusitis AcuteSinusitis PersistentSurveillance of AMR in the communitySuspected Infection in The ElderlyTonsillitis/PharyngitisTuberculosisUTI RecurrentUTIsVaginal Discharge

2.  Please specify up to three conditions/illnesses not mentioned that you think require further research On a scale of 1--5, please indicate how much more evidence you would like to see for your chosen illness/condition to support your daily clinical practice. (Tick one box for each statement) Optional extra 1Optional extra 2Optional extra 3

Section 2
=========

1.  From the list of illnesses/conditions you just rated, which top 3 illnesses/conditions do you feel require further research, evidence and guidance? Illness condition 1Illness condition 2Illness condition

2.  In relation to this illness/condition (respondents will only be shown their 3 selected illness/conditions), please indicate how important you feel improvements in each of the following areas are? Need for better evidence base for antibiotic treatment in primary careNeed for better evidence base for self-care and non-antibiotic treatment in primary careNeed for better near patient antibiotic resistance test in primary careNeed for improved treatment guidelines for primary care staffNeed for better clinical scores to help inform management in primary careNeed for better point of care prognostic tests in primary care

Section 3
=========

1.  How did you receive this questionnaire? Royal College of General Practitioners (RCGP)NIHR Clinical Research Network ((CRN) (Primary Care))Clinical Commissioning Group (CCG)ColleagueOther, please specify

2.  Age (years) 20--3031--4041--5051--6060+

3.  Sex MaleFemale

4.  How many years have you been a practicing GP? 0--56 to 1011 to 1516--2020+

5.  Did you carry out an antibiotic/infection audit in the past 12 months? YesNo

6.  Where are you a general practitioner? EnglandScotlandWalesNorthern Ireland

7.  Which region is your practice in?

    Please select one North EastNorth WestYorkshire and HumberEast MidlandsWest MidlandsEast of EnglandLondonSouth EastSouth West

8.  How would you describe your practice geographical location? ruralurbansuburban

9.  Is your practice a research practice? YesNo

antibiotics-09-00265-t0A1_Table A1

###### 

Comparison between researchers and non-researchers in Question 1 responses. The *p*-value obtained from the likelihood ratio test (LRT), except where indicated otherwise.

  Condition                           Responses          Non-Research   Research   Unadjusted   Adjusted                                                                       
  ----------------------------------- ------------------ -------------- ---------- ------------ ------------------------ ------------ ------------ --------------------------- -----------------
  AMR in returning travellers         Very Unimportant   20             22         OR 0.7       \[95% CI 0.48--1.01\];   *p* = 0.06   OR 0.76      \[95% CI 0.50--1.14\];      *p* = 0.18
  Unimportant                         44                 50                                                                                                                    
  Neutral                             55                 48                                                                                                                    
  Important                           39                 32                                                                                                                    
  Very important                      26                 14                                                                                                                    
  Cellulitis                          Very Unimportant   6              10         OR 0.99      \[95% CI 0.68--1.46\];   *p* = 0.98   OR 0.96      \[95% CI 0.63--1.45\];      *p* = 0.8
  Unimportant                         19                 16                                                                                                                    
  Neutral                             42                 34                                                                                                                    
  Important                           70                 72                                                                                                                    
  Very important                      42                 38                                                                                                                    
  Chlamydia genital                   Very Unimportant   16             17         OR 0.89      \[95% CI 0.61--1.31\];   *p* = 0.6    OR 0.92      \[95% CI 0.61--1.40\];      *p* = 0.7
  Unimportant                         40                 45                                                                                                                    
  Neutral                             75                 58                                                                                                                    
  Important                           40                 34                                                                                                                    
  Very important                      9                  12                                                                                                                    
  Cough (acute)                       Very Unimportant   19             17         OR 1.2       \[95% CI 0.82--1.74\];   *p* = 0.3    OR 1.29      \[95% CI 0.88--1.90\];      *p* = 0.19
  Unimportant                         36                 30                                                                                                                    
  Neutral                             47                 43                                                                                                                    
  Important                           49                 44                                                                                                                    
  Very important                      28                 35                                                                                                                    
  Cough (persistent)                  Very Unimportant   8              6          OR 1.2       \[95% CI 0.82--1.76\];   *p* = 0.3    OR 1.31      \[95% CI 0.89--1.95\];      *p* = 0.17 ^\*^
  Unimportant                         15                 11                                                                                                                    
  Neutral                             42                 35                                                                                                                    
  Important                           70                 69                                                                                                                    
  Very important                      47                 48                                                                                                                    
  Diverticulitis                      Very Unimportant   11             6          OR 1.11      \[95% CI 0.76--1.63\];   *p* = 0.6    OR 1.29      \[95% CI 0.85--1.95\];      *p* = 0.2 \*
  Unimportant                         23                 29                                                                                                                    
  Neutral                             58                 45                                                                                                                    
  Important                           63                 62                                                                                                                    
  Very important                      23                 25                                                                                                                    
  Epididymitis                        Very Unimportant   14             9          OR 1.03      \[95% CI 0.70--1.51\];   *p* = 0.9    1            \[95% CI 0.66--1.51\];      *p* = 0.99
  Unimportant                         28                 34                                                                                                                    
  Neutral                             70                 63                                                                                                                    
  Important                           54                 44                                                                                                                    
  Very important                      13                 19                                                                                                                    
  Community fungal nail infection     Very Unimportant   38             29         OR 0.97      \[95% CI 0.67--1.40\];   *p* = 0.9    OR 1.19      \[95% CI 0.80--1.78\];      *p* = 0.4
  Unimportant                         32                 43                                                                                                                    
  Neutral                             40                 37                                                                                                                    
  Important                           46                 40                                                                                                                    
  Very important                      25                 23                                                                                                                    
  Hepatitis viral                     Very Unimportant   16             11         OR 0.98      \[95% CI 0.67--1.43\];   *p* = 0.9    OR 0.98^x^   \[95% CI 0.67--1.43^x^\];   *p* = 0.9 ^x^
  Unimportant                         38                 42                                                                                                                    
  Neutral                             66                 62                                                                                                                    
  Important                           45                 31                                                                                                                    
  Very important                      17                 22                                                                                                                    
  HIV/AIDS                            Very Unimportant   15             16         OR 0.9       \[95% CI 0.61--1.31\];   *p* = 0.6    OR 0.90^x^   \[95% CI 0.61--1.31^x^\];   *p* = 0.6 ^x^
  Unimportant                         43                 44                                                                                                                    
  Neutral                             64                 56                                                                                                                    
  Important                           38                 23                                                                                                                    
  Very important                      20                 25                                                                                                                    
  Infection in returning travellers   Very Unimportant   13             11         OR 0.78      \[95% CI 0.53--1.13\];   *p* = 0.19   OR 0.83      \[95% CI 0.55--1.25\];      *p* = 0.4
  Unimportant                         34                 44                                                                                                                    
  Neutral                             60                 56                                                                                                                    
  Important                           50                 42                                                                                                                    
  Very important                      23                 17                                                                                                                    
  Insect bites                        Very Unimportant   19             21         OR 0.98      \[95% CI 0.68--1.43\];   *p* = 0.9    OR 1.17      \[95% CI 0.78--1.76\];      *p* = 0.5 \*
  Unimportant                         43                 44                                                                                                                    
  Neutral                             63                 46                                                                                                                    
  Important                           43                 45                                                                                                                    
  Very important                      12                 13                                                                                                                    
  Leg ulcers                          Very Unimportant   5              7          OR 1.12      \[95% CI 0.77--1.64\];   *p* = 0.5    OR 1.11      \[95% CI 0.73--1.67\];      *p* = 0.6 \*
  Unimportant                         15                 15                                                                                                                    
  Neutral                             38                 35                                                                                                                    
  Important                           76                 56                                                                                                                    
  Very important                      48                 58                                                                                                                    
  Lyme disease                        Very Unimportant   16             13         OR 0.91      \[95% CI 0.62--1.32\];   *p* = 0.6    OR 1.03      \[95% CI 0.68--1.55\];      *p* = 0.9
  Unimportant                         32                 44                                                                                                                    
  Neutral                             62                 50                                                                                                                    
  Important                           43                 38                                                                                                                    
  Very important                      24                 25                                                                                                                    
  Mastitis                            Very Unimportant   19             21         OR 0.91      \[95% CI 0.62--1.32\];   *p* = 0.6    OR 0.91^x^   \[95% CI 0.62--1.32^x^\];   *p* = 0.6 ^x^
  Unimportant                         40                 41                                                                                                                    
  Neutral                             74                 60                                                                                                                    
  Important                           38                 38                                                                                                                    
  Very important                      11                 9                                                                                                                     
  Otitis external                     Very Unimportant   17             21         OR 0.91      \[95% CI 0.64--1.36\];   *p* = 0.7    OR 0.99      \[95% CI 0.67--1.47\];      *p* = 0.97 \*
  Unimportant                         37                 36                                                                                                                    
  Neutral                             51                 40                                                                                                                    
  Important                           55                 45                                                                                                                    
  Very important                      22                 25                                                                                                                    
  Otitis media                        Very Unimportant   19             20         OR 0.96      \[95% CI 0.66--1.39\];   *p* = 0.8    OR 1.06      \[95% CI 0.70--1.59\];      *p* = 0.8 \*
  Unimportant                         46                 41                                                                                                                    
  Neutral                             51                 46                                                                                                                    
  Important                           46                 48                                                                                                                    
  Very important                      22                 16                                                                                                                    
  Prostatitis                         Very Unimportant   11             3          OR 1.6       \[95% CI 1.09--2.34\];   *p* = 0.02   OR 1.53      1.02--2.32\];               *p* = 0.04 \*
  Unimportant                         21                 22                                                                                                                    
  Neutral                             77                 54                                                                                                                    
  Important                           52                 60                                                                                                                    
  Very important                      21                 30                                                                                                                    
  Sinusitis (acute)                   Very Unimportant   22             19         OR 0.99      \[95% CI 0.68--1.44\];   *p* = 0.9    OR 1.12      \[95% CI 0.75--1.69\];      *p* = 0.6
  Unimportant                         39                 38                                                                                                                    
  Neutral                             49                 45                                                                                                                    
  Important                           43                 49                                                                                                                    
  Very important                      26                 18                                                                                                                    
  Sinusitis (persistent)              Very Unimportant   9              8          OR 0.96      \[95% CI 0.66--1.42\];   *p* = 0.8    OR 1.19      \[95% CI 0.78--1.82\];      *p* = 0.4
  Unimportant                         20                 17                                                                                                                    
  Neutral                             43                 45                                                                                                                    
  Important                           75                 67                                                                                                                    
  Very important                      31                 28                                                                                                                    
  Surveillance of AMR in community    Very Unimportant   5              7          OR 1.16      \[95% CI 0.79--1.72\];   *p* = 0.4    OR 1.31      \[95% CI 0.86--2.02\];      *p* = 0.2
  Unimportant                         15                 12                                                                                                                    
  Neutral                             22                 19                                                                                                                    
  Important                           58                 46                                                                                                                    
  Very important                      81                 85                                                                                                                    
  Suspected infection in elderly      Very Unimportant   6              1          OR 1.19      \[95% CI 0.81--1.76\];   *p* = 0.4    OR 1.4       \[95% CI 0.91--2.16\];      *p* = 0.13 \*
  Unimportant                         8                  7                                                                                                                     
  Neutral                             23                 19                                                                                                                    
  Important                           74                 71                                                                                                                    
  Very important                      72                 71                                                                                                                    
  Tonsillitis                         Very Unimportant   25             30         OR 0.89      \[95% CI 0.61--1.29\];   *p* = 0.5    OR 0.94      \[95% CI 0.62--1.41\];      *p* = 0.8
  Unimportant                         49                 44                                                                                                                    
  Neutral                             52                 48                                                                                                                    
  Important                           43                 34                                                                                                                    
  Very important                      12                 14                                                                                                                    
  Tuberculosis                        Very Unimportant   18             19         OR 0.82      \[95% CI 0.56--1.19\];   *p* = 0.3    0.85         \[95% CI 0.57--1.29\];      *p* = 0.5
  Unimportant                         36                 41                                                                                                                    
  Neutral                             58                 56                                                                                                                    
  Important                           54                 31                                                                                                                    
  Very important                      15                 21                                                                                                                    
  UTI (recurrent)                     Very Unimportant   4              5          1.22         \[95% CI 0.83--1.79\];   *p* = 0.3    1.38         \[95% CI 0.91--2.12\];      *p* = 0.13 \*
  Unimportant                         6                  6                                                                                                                     
  Neutral                             34                 23                                                                                                                    
  Important                           74                 70                                                                                                                    
  Very important                      64                 68                                                                                                                    
  UTIs                                Very Unimportant   13             12         1.05         \[95% CI 0.72--1.54\];   *p* = 0.8    1.2          \[95% CI 0.79--1.80\];      *p* = 0.4
  Unimportant                         33                 28                                                                                                                    
  Neutral                             53                 55                                                                                                                    
  Important                           58                 38                                                                                                                    
  Very important                      26                 34                                                                                                                    
  Vaginal discharge                   Very Unimportant   10             10         1            \[95% CI 0.68--1.46\];   *p* = 0.98   1.19         \[95% CI 0.78--1.80\];      *p* = 0.4 \*
  Unimportant                         32                 32                                                                                                                    
  Neutral                             64                 61                                                                                                                    
  Important                           55                 43                                                                                                                    
  Very important                      15                 21                                                                                                                    

\* Wald *p*-value ^x^ Unadjusted.

![Survey response rate by area in England.](antibiotics-09-00265-g001){#antibiotics-09-00265-f001}

![Condition ranking presented as a percentage of the total possible score for each condition. Condition ranking is the total scores for each illness (where 1 = further research unimportant, 5 = further research very important) were converted into a percentage by dividing the total score by the maximum possible score, i.e., as if all respondents indicated that further research into that illness was 'very important'.](antibiotics-09-00265-g002){#antibiotics-09-00265-f002}

antibiotics-09-00265-t001_Table 1

###### 

Respondent reported age, sex and number of years in practice compared to national data, where available. Statistical comparisons made using the Chi-square test (significant at the 5% level).

  Variable                              Survey (a)(b)   England (c)(d) \[[@B11-antibiotics-09-00265]\] \*                  
  ------------------------------------- --------------- --------------------------------------------------- -------------- -----
  **Age** (*p* = 0.260)                 *n* = 367                                                           *n* = 44,047   
  20--30                                17              5%                                                  2110           5%
  31--40                                106             29%                                                 10,363         31%
  41--50                                103             28%                                                 9629           28%
  51--60                                110             30%                                                 8677           24%
  60+                                   31              8%                                                  2677           8%
  Unknown                                               \-                                                  1485           3%
  **Sex** (*p* = 0.183)                 *n* = 363                                                           *n* = 43,966   
  Male                                  150             41%                                                 19,213         44%
  Female                                213             59%                                                 23,659         54%
  Unknown                                                                                                   1094           2%
  **Research Practice** (*p* = 0.019)   *n* = 361                                                           *n* = 7840     
  Yes                                   174             48%                                                 3293           42%
  No                                    187             52%                                                 4547           58%
  **Years in practice**                 *n* = 362                                                                          
  0--5                                  75              21%                                                 \-             \-
  6--10                                 59              16%                                                 \-             \-
  11--15                                59              16%                                                 \-             \-
  16--20                                45              12%                                                 \-             \-
  20+                                   124             34%                                                 \-             \-
  **Region** \* (*p* =\< 0.05)          *n* = 288                                                           *n* = 44,737   
  North East                            13              4%                                                  2159           5%
  North West                            35              12%                                                 5878           13%
  Yorkshire and Humber                  14              5%                                                  4364           10%
  East Midlands                         22              8%                                                  3490           8%
  West Midlands                         36              12%                                                 4634           10%
  East of England                       11              4%                                                  4463           10%
  London                                28              10%                                                 7175           16%
  South East                            55              19%                                                 7417           17%
  South West                            74              26%                                                 4354           10%
  Unknown                                                                                                   803            2%
  **Locality**                          *n* = 360                                                                          
  urban                                 166             46%                                                 \-             \-
  suburban                              140             39%                                                 \-             \-
  rural                                 54              15%                                                 \-             \-

\(a\) Missing data removed. (b) Survey data completed by each respondent. (c) Reference data from NHS digital General Practice Workforce Final 31 December 2018, Experimental Statistics GP Tables Final---December 2018 (<https://files.digital.nhs.uk/C4/7AD1A0/GPWDec18GP_v3.xlsx>) (d) Research Practice Reference research data from the National Institute for Health research (NIHR) report in 2017. \* There was no directly comparable data by region; therefore, reference data is by Health Education England (HEE) regions with Wessex being included in the South East.

antibiotics-09-00265-t002_Table 2

###### 

All 27 named illnesses/conditions in order of importance for further evidence to support daily practice.

  Order of Importance for Evidence to Support Daily Practice   Condition/Illness   Top 3 Ranked by the Need for More Research, Evidence and Guidance                                                  
  ------------------------------------------------------------ ------------------- ------------------------------------------------------------------- ----------------------------------------- ---- -----
  415                                                          1                   \-                                                                  Suspected infection in the elderly        1    115
  417                                                          2                   18                                                                  UTI (recurrent)                           2    107
  413                                                          3                   3                                                                   Surveillance of AMR in the community      1    115
  418                                                          4                   5                                                                   Leg ulcers                                5    70
  413                                                          5                   17                                                                  Cough (persistent)                        3    94
  414                                                          6                   28                                                                  Cellulitis                                4    89
  404                                                          7                   6                                                                   Sinusitis (persistent)                    9    28
  412                                                          8                   \-                                                                  Prostatitis                               7    36
  408                                                          9                   \-                                                                  Diverticulitis                            8    30
  412                                                          10                  18                                                                  UTIs                                      10   25
  409                                                          11                  17                                                                  Cough (acute)                             6    47
  406                                                          12                  4                                                                   Vaginal discharge                         8    18
  409                                                          13                  1                                                                   Lyme disease                              9    28
  411                                                          14                  \-                                                                  Epididymitis/Orchitis                     13   20
  411                                                          15                  7                                                                   Otitis externa                            12   22
  413                                                          16                  11                                                                  Infection in returning travelers          11   23
  410                                                          17                  6                                                                   Sinusitis (acute)                         17   13
  414                                                          18                  24                                                                  Hepatitis viral                           14   19
  411                                                          19                  19                                                                  Tuberculosis                              18   8
  406                                                          20                  14                                                                  HIV/AIDS                                  15   16
  418                                                          21                  7                                                                   Otitis media                              16   15
  413                                                          22                  \-                                                                  Insect Bites, possible skin infections    16   15
  408                                                          23                  1                                                                   Chlamydia genital                         20   4
  415                                                          24                  26                                                                  Fungal nail infections in the community   22   23
  415                                                          25                  \-                                                                  Mastitis                                  19   7
  415                                                          26                  \-                                                                  AMR in returning travelers                10   25
  414                                                          27                  10                                                                  Tonsillitis/Pharyngitis                   19   7

antibiotics-09-00265-t003_Table 3

###### 

Evidence, research and guidance needs, ranked in order of importance, for each named condition. Conditions are listed in order of importance for further research, as outlined in [Table 2](#antibiotics-09-00265-t002){ref-type="table"}.

  Condition                                 Need for Better Evidence Base for Antibiotic Treatment in Primary Care   Need for Better Evidence Base for Self-Care and Non-Antibiotic Treatment in Primary Care   Need for Better Near Patient Antibiotic Resistance Test in Primary Care   Need for Improved Treatment Guidelines for Primary Care Staff   Need for Better Clinical Scores to Help Inform Management in Primary Care   Need For Better Point of Care Prognostic Tests In Primary Care                             
  ----------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------- --- ------ --- ------ --- ------
  Suspected infection in the elderly        1                                                                        4.58                                                                                       4                                                                         4.25                                                            5                                                                           4.16                                                             2   4.46   6   4.15   3   4.38
  UTI (recurrent)                           2                                                                        4.50                                                                                       1                                                                         4.53                                                            5                                                                           4.15                                                             3   4.37   6   3.94   4   4.16
  Surveillance of AMR in the community      1                                                                        4.64                                                                                       2                                                                         4.60                                                            4                                                                           4.25                                                             5   4.21   6   3.98   3   4.27
  Leg Ulcers                                2                                                                        4.46                                                                                       3                                                                         4.43                                                            5                                                                           3.92                                                             1   4.52   4   4.03   6   3.91
  Cough (persistent)                        3                                                                        4.31                                                                                       1                                                                         4.43                                                            6                                                                           3.76                                                             2   4.42   5   4.02   4   4.05
  Cellulitis                                1                                                                        4.61                                                                                       3                                                                         4.28                                                            6                                                                           3.92                                                             2   4.37   4   4.09   5   4.03
  Sinusitis (persistent)                    3                                                                        4.17                                                                                       1                                                                         4.54                                                            6                                                                           3.33                                                             2   4.42   4   3.87   5   3.52
  Prostatitis                               1                                                                        4.65                                                                                       3                                                                         3.94                                                            5                                                                           3.53                                                             2   4.38   3   3.94   4   3.74
  Diverticulitis                            1                                                                        4.48                                                                                       3                                                                         4.40                                                            6                                                                           3.33                                                             2   4.41   4   4.07   5   3.70
  UTIs                                      2                                                                        4.54                                                                                       1                                                                         4.67                                                            4                                                                           4.33                                                             3   4.39   5   4.08   6   4.00
  Cough (acute)                             2                                                                        4.44                                                                                       1                                                                         4.57                                                            6                                                                           3.90                                                             4   4.24   5   4.02   3   4.26
  Vaginal Discharge                         2                                                                        4.57                                                                                       3                                                                         4.17                                                            4                                                                           3.86                                                             1   4.71   6   3.57   5   3.71
  Lyme Disease                              2                                                                        4.50                                                                                       5                                                                         3.71                                                            6                                                                           3.08                                                             1   4.54   4   3.85   3   3.92
  Epididymitis/Orchitis                     1                                                                        4.42                                                                                       3                                                                         4.05                                                            5                                                                           3.74                                                             2   4.37   4   3.88   6   3.68
  Otitis Externa                            2                                                                        4.20                                                                                       2                                                                         4.20                                                            5                                                                           3.25                                                             1   4.42   3   3.95   4   3.60
  Infection In Returning Travellers         1                                                                        4.57                                                                                       3                                                                         4.20                                                            6                                                                           4.00                                                             2   4.48   5   4.05   4   4.19
  Sinusitis (acute)                         2                                                                        4.50                                                                                       1                                                                         4.62                                                            5                                                                           3.58                                                             3   4.00   4   3.85   3   4.00
  Hepatitis (viral)                         5                                                                        3.07                                                                                       3                                                                         3.64                                                            6                                                                           2.53                                                             1   4.21   2   4.20   3   3.67
  Tuberculosis                              1                                                                        4.43                                                                                       5                                                                         3.57                                                            4                                                                           3.86                                                             1   4.43   2   4.14   3   4.00
  HIV/AIDS                                  4                                                                        3.93                                                                                       2                                                                         4.14                                                            5                                                                           3.57                                                             1   4.36   4   3.93   3   4.00
  Otitis Media                              2                                                                        4.58                                                                                       1                                                                         4.67                                                            6                                                                           3.92                                                             3   4.50   4   4.25   5   4.00
  Insect Bites, possible skin infections    2                                                                        4.29                                                                                       1                                                                         4.50                                                            5                                                                           3.57                                                             3   3.93   4   3.79   3   3.93
  Chlamydia (genital)                       2                                                                        4.00                                                                                       4                                                                         2.33                                                            1                                                                           4.33                                                             3   3.00   4   2.33   2   4.00
  Fungal nail infections in the community   3                                                                        3.84                                                                                       1                                                                         4.47                                                            5                                                                           3.16                                                             2   4.37   4   3.32   4   3.32
  Mastitis                                  2                                                                        4.20                                                                                       3                                                                         3.75                                                            6                                                                           2.80                                                             1   4.40   4   3.67   5   3.40
  AMR in returning travellers               2                                                                        4.36                                                                                       3                                                                         4.25                                                            3                                                                           4.25                                                             1   4.42   4   4.09   5   4.04
  Tonsillitis/Pharyngitis                   2                                                                        4.50                                                                                       1                                                                         4.67                                                            5                                                                           3.33                                                             3   4.17   3   4.17   4   3.83
  Overall scoring                           1                                                                        4.35                                                                                       3                                                                         4.21                                                            5                                                                           3.68                                                             2   4.31   4   3.90   4   3.90
